Compare iShares MSCI Germany (DAX) (EWG) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs GSK plc — how do they compare? iShares MSCI Germany (DAX) trades at $41.12, while GSK plc trades at $52.54 (market cap $101.34B). The key difference: GSK plc pays a 3.49% dividend while iShares MSCI Germany (DAX) pays none, and GSK plc is trading nearer its 52-week high, iShares MSCI Germany (DAX) nearer its low. Which is the better fit depends on your goals.
| EWG | GSK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $44.56 | $61.18 |
52-Week Low | $38.08 | $36.20 |
Market Cap | — | $101.34B |
Enterprise Value | — | $121.95B |
Dividend Yield | — | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG trades at $41.10, down 0.7% on the day, with a neutral technical signal and bearish moving averages. Key support is at $41 and resistance at $42. The stock lacks available financial ratios, and a dividend of $0.83 is scheduled for June 2026. Recent news highlights German economic policies and ECB rate decisions influencing European market sentiment.
The outlook is cautious due to limited fundamental data and mixed technical indicators. Risks include macroeconomic volatility from energy prices and ECB policy shifts. Analyst sentiment is neutral, with no clear consensus on price targets or ratings available.
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
